Nature CommunicationsGenomicsPeer-reviewed journal article
Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma
Kylee H. MaclachlaniD, Even Holth Rustad, Andriy DerkachiD, Binbin Zheng-LiniD, Venkata D. YellapantulaiD, Benjamin T. DiamondiD, Malin L. HultcrantziD, Bachisio ZicchedduiD, Eileen Mary BoyleiD, Patrick BlaneyiD, Niccolò BolliiD, Yanming ZhangiD, Ahmet DoǧaniD, Alexander M. LesokhiniD, Gareth John MorganiD, Ola LandgreniD, Francesco MauraiD
Abstract
Chromothripsis is detectable in 20-30% of newly diagnosed multiple myeloma (NDMM) patients and is emerging as a new independent adverse prognostic factor. In this study, we interrogate 752 NDMM patients using whole genome sequencing (WGS) to study the relationship of copy number (CN) signatures to chromothripsis and show they are highly associated. CN signatures are highly predictive of the presence of chromothripsis (AUC=0.90) and can be used to identify its adverse prognostic impact. The ability of CN signatures to predict the presence of chromothripsis was confirmed in a validation series of WGS comprised of 235 hematological cancers (AUC=0.97) and an independent series of 34 NDMM (AUC=0.87). We show that CN signatures can also be derived from whole exome data (WES) and using 677 cases from the same series of NDMM, we were able to predict both the presence of chromothripsis (AUC=0.82) and its adverse prognostic impact. CN signatures constitute a flexible tool to identify the presence of chromothripsis and is applicable to WES and WGS data.
- organism: human
- assay: whole-genome sequencing
- assay: whole-exome sequencing
- research focus: differential expression
- research focus: variant calling
- research focus: protein structure prediction
- approach: statistical model
- Citations
- 49
- FWCI
- 5.22
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
Francesco Maura, Marcella Kaddoura, … Niels Weinhold·Nature GeneticsPeer-reviewed·Aug 20, 2025
- Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition
- Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma
Lucía Peña‐Pérez, Nicolai Sebastian Frengen, … Robert Månsson·Blood AdvancesPeer-reviewed·Jun 8, 2022
- High WEE1 expression is independently linked to poor survival in multiple myeloma
Anish K. Simhal, R. S. Firestone, … Joseph O. Deasy·Blood Cancer JournalPeer-reviewed·Feb 20, 2025
- Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms
B. T. Diamond, B. Ziccheddu, … F. Maura·bioRxiv·Apr 26, 2022
- Sequential acquisition of 1p31.1-p12 LOH and 1q Gain is a common double-hit event in relapsed/refractory myeloma
Naser Ansari‐Pour, Sarah Gooding, … Anjan Thakurta·bioRxiv·May 21, 2026